Centers for Medicare & Medicaid Services

CMS, Medicaid Expand 2026 Coverage for Five Emerging Health Technologies

by
CMS issues major 2026 reimbursement changes impacting neuromodulation, EP ablation, wound care, sleep apnea therapy, and DKD diagnostics across the U.S.

Broader 2026 Coverage Enhances Economics Across Multiple Care Settings A sweeping set of CMS and Medicaid reimbursement decisions is reshaping 2026 access across neuromodulation, electrophysiology, advanced wound reconstruction, diagnostic testing, and regenerative biologics. From APC assignments and ASC approvals to national pricing and expanded Medicaid coverage, these updates strengthen commercial readiness for emerging technologies while … Read more

Reimbursement Series: CMS and Europe Reimbursement Pathway Accelerates Innovation

by
CMS and Europe reimbursement pathway

In a transformative week for market access, the CMS and Europe reimbursement pathway expansion delivered several pivotal coverage and pricing decisions reshaping patient access across cardiovascular, hepatic, and oncology therapies. From CMS’s national determinations on breakthrough devices to European HTA approvals in rare disease and cancer, these developments underscore a growing transatlantic alignment between regulators … Read more

Medicare Expands Signatera Genome MRD Assay Coverage

by

Medicare has approved coverage for Natera’s genome-based Signatera molecular residual disease (MRD) assay under LCD L38779, extending access to beneficiaries across six cancer indications. The coverage applies to colorectal, breast, bladder, ovarian, and lung cancers, as well as pan-cancer immunotherapy monitoring, aligning with the scope of Natera’s original Signatera test. This regulatory milestone positions the … Read more